' Encouraging ' Data on Ipilimumab Plus Anti-PD-1 in Metastatic Melanoma ' Encouraging ' Data on Ipilimumab Plus Anti-PD-1 in Metastatic Melanoma
For patients with advanced melanoma resistant to anti-PD-L1 monotherapy, combining the CTLA-4 inhibitor ipilimumab with an anti-PD-1 agent ' should be favored ' over ipilimumab alone as second-line immunotherapy, researchers say.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Health | Hematology | Immunotherapy | Melanoma | Skin Cancer | Yervoy